AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
BofA said concerns about adoption of Axsome’s Alzheimer’s agitation treatment and its ability to meet full-year 2027 revenue estimates have weighed on shares.
BofA said concerns about adoption of Axsome’s Alzheimer’s agitation treatment and its ability to meet full-year 2027 revenue estimates have weighed on shares.